Abstract
© 2015 Informa UK, Ltd. In the era of biologic therapies, methotrexate (MTX), a classic immunomodulator, is still the cornerstone of systemic treatment of psoriasis. MTX has been used for many years, achieving good responses with a good safety profile. However, only a few randomized clinical trials have been performed involving MTX, and most of the current evidence comes from pivotal studies of biologic drugs. The aim of this article is to make an extensive review of the MTX mechanism of action, pharmacokinetics, efficacy, safety and tolerability, especially focusing on the future perspective of this old drug and recent advances in the field of pharmacogenetics.
| Original language | English |
|---|---|
| Pages (from-to) | 553-563 |
| Journal | Expert Review of Clinical Immunology |
| Volume | 11 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 1 May 2015 |
Keywords
- Adenosine
- Dihydrofolate reductase inhibitor
- Folic acid
- Methotrexate
- Methotrexate polyglutamates
- Pharmacogenetics
- Psoriasis
Fingerprint Dive into the research topics of 'Systemic methotrexate for the treatment of psoriasis'. Together they form a unique fingerprint.
Cite this
Yélamos, O., & Puig, L. (2015). Systemic methotrexate for the treatment of psoriasis. Expert Review of Clinical Immunology, 11(5), 553-563. https://doi.org/10.1586/1744666X.2015.1026894